Skip to main content
Arcus Logo
  • About Us
    • About Arcus
    • Leadership
    • Board of Directors
    • Scientific Advisory Board
    • Contact Us
  • Our Science
    • See Pipeline
    • Discovery Candidates
    • Clinical Candidates
      • Anti-TIGIT
      • domvanalimab
      • AB308
      • Adenosine Pathway
      • etrumadenant
      • quemliclustat
      • Anti-PD1
      • zimberelimab
      • HIF-2⍺
      • AB521
    • Clinical Trials
      • Investigator Sponsored
      • Expanded Access Program
    • Publications
  • Editorials
  • Careers
  • Investors & Media
    • Press Releases
    • Events & Presentations
      • Events Calendar
      • Corporate Presentation
    • Stock Information
      • Analyst Coverage
      • Stock Information
    • SEC Filings
    • Corporate Governance
      • Governance Documents
      • Management Team
      • Board of Directors
      • Committee Composition
    • Contact Investor Relations
      • Contact Investor Relations
      • FAQs
      • Email Alerts

Committee Composition

molecules molecules molecules
  • About Us
    • About Arcus
    • Leadership
    • Board of Directors
    • Scientific Advisory Board
    • Contact Us
  • Our Science
    • See Pipeline
    • Discovery Candidates
    • Clinical Candidates
      • Anti-TIGIT
      • domvanalimab
      • AB308
      • Adenosine Pathway
      • etrumadenant
      • quemliclustat
      • Anti-PD1
      • zimberelimab
      • HIF-2⍺
      • AB521
    • Clinical Trials
      • Investigator Sponsored
      • Expanded Access Program
    • Publications
  • Editorials
  • Careers
  • Investors & Media
    • Press Releases
    • Events & Presentations
      • Events Calendar
      • Corporate Presentation
    • Stock Information
      • Analyst Coverage
      • Stock Information
    • SEC Filings
    • Corporate Governance
      • Governance Documents
      • Management Team
      • Board of Directors
      • Committee Composition
    • Contact Investor Relations
      • Contact Investor Relations
      • FAQs
      • Email Alerts

Investor Contact

investorinfo@arcusbio.com

Investor Email Alerts

To receive notifications via email, enter your email address and select at least one subscription below. After submitting your information, you will receive an email. You must click the link in the email to activate your subscription. You can sign up for additional subscriptions at any time.

* Required

*
*



Email Alert Sign Up Confirmation

Explore More

Read our latest press releases and announcements

Browse

Join forces with us on our mission to defeat cancer

Connect

Arcus clinical trials are currently enrolling

Sign up
Arcus Logo

Arcus Biosciences is a registered trademark of Arcus Biosciences, Inc.
© Arcus Biosciences, Inc.  All rights reserved.
3928 Point Eden Way, Hayward, CA 94545

  • About Us
  • Our Science
  • Editorials
  • Careers
  • Investors & Media
  • Contact
  • Privacy Policy
  • Cookie Policy
  • Terms of Use
  • Sitemap
  • DO NOT SELL/SHARE MY PERSONAL INFORMATION
  • Email icon
  • Twitter icon
  • Linkedin icon
Powered By Q4 Inc. 5.104.0.1 (opens in new window)